Biocryst Pharmaceuticals (BCRX) Debt Ratio (2011 - 2026)

Biocryst Pharmaceuticals has reported Debt Ratio for 16 years, with the latest figure at 0.94 in Q1 2026.

• For the quarter ending Q1 2026, Debt Ratio rose 28.55% year-over-year to 0.94; the trailing twelve-month figure through Mar 2026 stood at 0.94 (up 28.55% YoY), and the FY2025 full-year result was 0.07, down 89.45% from the prior year.
• Debt Ratio for Q1 2026 stood at 0.94, up from 0.07 in the prior quarter.
• The five-year high for Debt Ratio was 0.94 in Q1 2026, with the low at 0.07 in Q4 2025.
• Historically, Debt Ratio has averaged 0.55 across 5 years, with a median of 0.57 in 2023.
• Annual changes were most pronounced in 2023 — Debt Ratio jumped 95.46% — and 2025, when it sank 89.45%.
• Biocryst Pharmaceuticals' Debt Ratio stood at 0.42 in 2022, then jumped by 50.11% to 0.63 in 2023, then climbed by 12.1% to 0.71 in 2024, then slumped by 89.45% to 0.07 in 2025, then soared by 1152.12% to 0.94 in 2026.
• The last three Debt Ratio figures came in at 0.94 (Q1 2026), 0.07 (Q4 2025), and 0.52 (Q3 2025), per Business Quant data.